Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Increases Position in IQVIA Holdings Inc. (NYSE:IQV)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 132.4% during the third quarter, HoldingsChannel reports. The fund owned 15,210 shares of the medical research company’s stock after acquiring an additional 8,665 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in IQVIA were worth $3,604,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. 1832 Asset Management L.P. grew its stake in IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after buying an additional 376,595 shares during the last quarter. Renaissance Technologies LLC purchased a new position in IQVIA during the 2nd quarter worth $70,610,000. Impax Asset Management Group plc grew its stake in IQVIA by 19.3% during the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after buying an additional 264,555 shares during the last quarter. Canada Pension Plan Investment Board grew its stake in IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after buying an additional 211,653 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. grew its stake in IQVIA by 285.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock worth $56,783,000 after buying an additional 198,808 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.60% of the stock is owned by company insiders.

IQVIA Price Performance

Shares of IQVIA stock traded up $1.62 on Wednesday, hitting $217.96. The company’s stock had a trading volume of 64,402 shares, compared to its average volume of 1,067,250. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The firm has a fifty day moving average price of $236.50 and a 200-day moving average price of $230.16. The company has a market capitalization of $39.73 billion, a price-to-earnings ratio of 28.10, a price-to-earnings-growth ratio of 2.09 and a beta of 1.49.

Analyst Ratings Changes

Several brokerages recently weighed in on IQV. Royal Bank of Canada started coverage on IQVIA in a research note on Wednesday, September 4th. They set an “outperform” rating and a $275.00 target price on the stock. Barclays lowered their price target on IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research report on Tuesday, October 15th. Morgan Stanley lifted their price target on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and lowered their price target for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. Finally, Truist Financial lowered their price target on IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a research report on Monday, October 14th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $267.27.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.